Clinical trials: Peripheral Nervous System Diseases
Painful Diabetic Peripheral Neuropathy (PDPN)
Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy
The purpose of this study is to assess analgesic efficacy of ASP3662 relative to placebo in subjects with painful diabetic peripheral neuropathy (PDPN) as well as assess the safety and tolerability of ASP3662 relative to placebo.
- Trial name
- NCT02372578
- Testing
- ASP3662, pregabalin
- Where
- 37 sites in United States
- Volunteers
- 115 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Painful Diabetic Neuropathy
An Open-label follow-on Trial to Assess the Long-term Safety and Efficacy of Oral SPM 927 in Subjects With Diabetic Neuropathy
The primary objective of the trial is to assess the tolerability and safety of long-term SPM 927 administration in subjects with diabetic neuropathy.
- Trial name
- NCT00861042
- Testing
- SPM927/Lacosamide
- Volunteers
- 69 people
- Sponsor
- UCB Pharma
Cancer
Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations
This was a 4-part (Part A, Part B, Part C and Part D), Phase I/IIa, multi-center, open label, study in pediatric subjects with refractory or recurrent tumors.
- Trial name
- NCT02124772
- Testing
- Trametinib, Dabrafenib
- Where
- 16 sites in United States, Australia and 3 more
- Volunteers
- 139 people
- Sponsor
- Novartis Pharmaceuticals
HIV Infections, Peripheral Nervous System Disease
Intranasal Peptide T in the Treatment of Painful Peripheral Neuropathy of AIDS
To compare the effects of intranasal peptide T and placebo in the treatment of painful peripheral neuropathy associated with human immunodeficiency virus (HIV) infection.
- Trial name
- NCT00002083
- Testing
- Peptide T
- Where
- 4 sites in United States
- Sponsor
- Advanced Peptides
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
The purpose of the study is to study the clinical effects of the investigational drug, SB-509 versus placebo in patients with diabetic neuropathy.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy
- Trial name
- NCT00476931
- Testing
- SB-509
- Where
- 20 sites in United States, Mexico
- Volunteers
- 91 people
- Sponsor
- Sangamo Therapeutics
Radiculopathy, Spondylolisthesis
Spondylolisthesis Treated With an iO-Flex® System Enabled Decompression
The purpose of this study is to evaluate the clinical performance of a decompression using the FDA cleared iO-Flex® System on-label in treating patients with spinal stenosis and stable grade I degenerative lumbar…
- Conditions
- Radiculopathy, Spondylolisthesis, Lumbar Spinal Stenosis
- Trial name
- STRiDE (NCT01338766)
- Testing
- Decompression using the iO-Flex® system
- Where
- 14 sites in United States
- Volunteers
- 100 people
- Sponsor
- Baxano Surgical, Inc.
Peripheral Nerve Disorder
Early Feasibility of the Nervonik Peripheral Nerve Stimulation Device
A multicenter, 30 patient prospective single arm evaluation of the Nervonik system in symptomatic patients with chronic severe knee, elbow or shoulder pain.
- Trial name
- NCT06772142
- Testing
- Peripheral Nerve Stimulation
- Where
- Panama
- Volunteers
- 30 people
- Sponsor
- Nervonik
Central Nervous System (CNS) Lesions, Brain Metastases
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
This Phase 2 clinical trial will study RVP-001, a new manganese-based MRI contrast agent, in people who are known to have gadolinium-enhancing central nervous system (CNS) lesions, for example brain tumors or multiple sclerosis.
- Conditions
- Central Nervous System (CNS) Lesions, Brain Metastases, Brain Neoplasms, Brain Neoplasms, Benign
- Trial name
- NCT06322342
- Testing
- RVP-001
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Reveal Pharmaceuticals Inc.
Chemotherapy-induced Peripheral Neuropathy
A Study of Topical Pirenzepine or Placebo in Oncology Patients With Chemotherapy Induced Peripheral Neuropathy
This is a randomized, double-blind, placebo-controlled adaptive study of the safety, tolerability, and exploratory efficacy of once-daily topical WST-057 administered for up to 19 weeks (or up to 24 weeks for subjects who…
- Trial name
- NCT05488873
- Testing
- WST-057 Active
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- WinSanTor, Inc
Painful Diabetic Neuropathies
Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy
The purpose of this study is to determine if Engensis (VM202) is safe and effective in treating painful diabetic neuropathy.
- Trial name
- NCT01475786
- Testing
- Low Dose: 16 mg Engensis (VM202), High Dose: 32 mg Engensis (VM202)
- Where
- 17 sites in United States, South Korea
- Volunteers
- 104 people
- Sponsor
- Helixmith Co., Ltd.
Cancer, Pancreatic Cancer
9-ING-41 in Patients With Advanced Cancers
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in…
- Conditions
- Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer
- Trial name
- NCT03678883
- Testing
- 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin.
- Where
- 66 sites in United States, Belgium and 5 more
- Volunteers
- 350 people
- Sponsor
- Actuate Therapeutics Inc.
Prostate Cancer, Ovarian Cancer
Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)
This study investigates the safety and efficacy of Acetyl-L-Carnitine and compares it to the safety and efficacy of a placebo (inactive) tablet in the prevention of Sagopilone-induced peripheral neuropathy.
- Trial name
- NCT00751205
- Testing
- Sagopilone 16 mg/m^2 i.v., Acetyl-L-Carnitine (ALC) 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid
- Where
- 22 sites in Belgium, France and 4 more
- Volunteers
- 150 people
- Sponsor
- Bayer
Sciatica
Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) Administered to Sciatica Participants
The primary objective of the study is to determine the safety/tolerability profile, systemic PK behavior, and immunogenicity of single IV and SC administrations of BG00010 to sciatica participants.
- Trial name
- NCT00961766
- Testing
- BG00010 (Neublastin)
- Where
- Australia
- Volunteers
- 48 people
- Sponsor
- Biogen
Postherpetic Neuralgia
Study of NGX-4010 With the Use of Open Label Lidocaine (2.5%)/Prilocaine (2.5%) Cream for the Treatment of Postherpetic Neuralgia (PHN)
This study is an open-label multi-center to evaluate the tolerability of treatment with NGX-4010 use with pre-patch topical application of a topical anesthetic cream. This is an open-label study.
- Trial name
- NCT00916942
- Testing
- capsaicin 8%, Lidocaine (2.5%)/Prilocaine (2.5%) Cream
- Where
- 6 sites in United States
- Volunteers
- 20 people
- Sponsor
- NeurogesX
Carpal Tunnel Syndrome (CTS)
Evaluation of Dynavisc in Pain Reduction Following Revision Surgery for Persistent or Recurrent Carpal Tunnel Syndrome
The trial will evaluate the efficacy of DYNAVISC in subjects with a diagnosis of persistent or recurrent carpal tunnel syndrome. This is a prospective, multicenter, randomized, evaluator-blinded clinical trial.
- Trial name
- NCT06593977
- Testing
- Dynavisc
- Where
- 4 sites in Belgium, Brazil and 1 more
- Volunteers
- 50 people
- Sponsor
- FzioMed
Neuropathic Pain, Pain
Optimized Programming in Spinal Cord Stimulation (SCS) System
The objective of this study is to evaluate extent, location, and perception of paresthesia as a function of anode/cathode configuration.
- Trial name
- OP (NCT00871819)
- Testing
- Precision Spinal Cord Stimulation (SCS)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boston Scientific Corporation
Recurrent and Refractory Solid Tumors
Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
Phase 1 of this study, utilizing a rolling 6 design, will be conducted to determine a maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), and to describe the toxicities of lenvatinib administered in combination with…
- Trial name
- NCT03245151
- Testing
- Lenvatinib, Everolimus
- Where
- 50 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- Eisai Inc.
Solid Tumor
Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)
This is a single sequence 2-period open label study in participants with advanced solid tumors. The purpose of Period 1 of this study is to assess the mass balance to determine drug-related entities present in circulation and…
- Trial name
- NCT06308263
- Testing
- Tuvusertib [14C]Tuvusertib microtracer, Tuvusertib, Tuvusertib + [14C]Tuvusertib microdose bolus injection
- Where
- Hungary
- Volunteers
- 12 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Amyloidosis, Amyloid Cardiomyopathy
Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy
Phase 3 efficacy and safety study to evaluate acoramidis (AG10) HCl 800 mg administered orally twice a day compared to placebo in subjects with symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
- Conditions
- Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies
- Trial name
- ATTRibute-CM (NCT03860935)
- Testing
- acoramidis
- Where
- 104 sites in United States, Australia and 16 more
- Volunteers
- 632 people
- Sponsor
- Eidos Therapeutics, a BridgeBio company
Peripheral Nerve Injuries
Registry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction
This study is a registry of general use of Avance Nerve Graft and is intended to evaluate the uses, response rates, and safety of Avance Nerve Graft in the real-life clinical setting.
- Trial name
- RANGER® (NCT01526681)
- Testing
- Processed Human Nerve Graft, Standard Treatment, Autogenous Nerve Graft, Direct Suture, etc., Autogenous Nerve Graft
- Where
- 49 sites in United States, Austria and 2 more
- Volunteers
- 3,126 people
- Sponsor
- Axogen Corporation